RPID — Rapid Micro Biosystems Income Statement
0.000.00%
Last trade - 00:00
- $29.78m
- -$49.46m
- $22.52m
- 25
- 61
- 26
- 30
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 16.5 | 16.1 | 23.2 | 17.1 | 22.5 |
Cost of Revenue | |||||
Gross Profit | -0.234 | -8.07 | -7.74 | -8.54 | -5.49 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 35.1 | 49.5 | 73.6 | 80.4 | 79.1 |
Operating Profit | -18.6 | -33.5 | -50.3 | -63.2 | -56.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.7 | -36.9 | -73.4 | -61.4 | -52.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.2 | -37.1 | -73.5 | -60.8 | -52.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -21.2 | -37.1 | -73.5 | -60.8 | -52.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.6 | -45.2 | -78 | -60.8 | -52.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.666 | -1.08 | -1.83 | -1.43 | -1.22 |
Dividends per Share |